Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 |
DateTitle 
11 May 2017Nexvet Biopharma plc ("Nexvet") Rule 2.10 Announcement
DUBLIN, Ireland, May 11, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following. In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover Rules, 2013 (the "Irish Takeover Rules"), Nexvet confirms that as at close of business on May 10, 2017 its issued share capital comprised 11,916,712 ordinary shares of $0.125 each (the “Ordinary Shares”). The Ordinary Shares are admitted to trading on NASDAQ under the ticker symbol NVET. The International ... 
Printer Friendly Version
11 May 2017Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2017
DUBLIN, Ireland, May 11, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three and nine month periods ended March 31, 2017. Recent highlights: In April 2017, entered into a Transaction Agreement for Zoetis to acquire all Nexvet shares for $6.72 per ordinary share in cash, valuing Nexvet at approximately $85 million Advanced key clinical programs and implemented a cost reduction program Signed a licensing agreement with Pfizer ... 
Printer Friendly Version
13 April 2017Zoetis to Acquire Nexvet Biopharma, an Innovator in Monoclonal Antibody Therapies for Companion Animals
Purchase price of US$6.72 per share, or approximately US$85 million in aggregate Acquisition to strengthen Zoetis’ pipeline in companion animal therapeutics for chronic pain, a global area estimated at US$400 million annually1 PARSIPPANY, N.J. & TULLAMORE, Ireland--(BUSINESS WIRE)--Apr. 13, 2017-- Zoetis Inc. (NYSE:ZTS) and Nexvet Biopharma plc (Nasdaq:NVET) today announced an agreement in which Zo... 
Printer Friendly Version
22 February 2017Nexvet to Present at the Cowen and Company 37th Annual Health Care Conference
DUBLIN, Ireland, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, Massachusetts on Monday, March 6th at 1:20PM ET. Dr. Heffernan will discuss Nexvet’s pivotal-stage clinical programs for chronic pain in cats and dogs, consisting of ranevetmab and frunevetmab; the significant progress made at the Company’s manufac... 
Printer Friendly Version
10 February 2017Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2017
DUBLIN, Ireland, Feb. 10, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three and six month periods ended December 31, 2016. Recent highlights: Initiated pivotal field efficacy and safety studies of frunevetmab, the Company’s anti-nerve growth factor monoclonal antibody (anti-NGF mAb) in development for the control of pain associated with osteoarthritis in cats Entered into a research collaboration with Genentech Successfull... 
Printer Friendly Version
Print Page    Email Page    RSS    Email Alerts    IR Contact    Tearsheet 

Nexvet Biopharma

Ireland
Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: + 353 5793 24522

Australia
Level 8, 31 Queen Street
Melbourne 3000
Victoria
P: +61 (3) 9610 4400

United States
275 Post Street
4th Floor
San Francisco, CA 94108

Email: info@nexvet.com